The latest update is out from BioNTech SE ( (BNTX) ).
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
BioNTech SE has reached a settlement agreement with the University of Pennsylvania over a royalty dispute related to its COVID-19 vaccine, developed in collaboration with Pfizer. The agreement involves a payment of up to $467 million to Penn, which includes royalties for past sales and funding for extended research collaboration. Pfizer has also agreed to reimburse BioNTech for part of these royalties.
More about BioNTech SE
BioNTech SE is a biotechnology company primarily focused on developing and manufacturing immunotherapies for the treatment of cancer and infectious diseases. The company is well-known for its role in developing one of the first COVID-19 vaccines in collaboration with Pfizer.
YTD Price Performance: 7.80%
Average Trading Volume: 820,259
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $27.28B
Learn more about BNTX stock on TipRanks’ Stock Analysis page.
